Bastiaans Diane E T, Immohr Laura I, Zeinstra Gertrude G, Strik-Albers Riet, Pein-Hackelbusch Miriam, van der Flier Michiel, de Haan Anton F J, Boelens Jaap Jan, Lankester Arjan C, Burger David M, Warris Adilia
Department of Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands.
Institute of Pharmaceutics and Biopharmaceutics, Heinrich-Heine-University, Düsseldorf, Germany.
Br J Clin Pharmacol. 2017 Dec;83(12):2789-2797. doi: 10.1111/bcp.13396. Epub 2017 Sep 20.
The palatability of a new paediatric formulation of valaciclovir was assessed in children and their parents: non-inferiority of the new paediatric formulation (test formulation) compared to the reference formulation was investigated.
In vivo palatability testing was performed in a randomized, two-period, multicentre, cross-over study. Children and their parents scored the liking of the new paediatric valaciclovir formulation and the reference formulation on a 100 mm visual analogue scale (VAS). To support formulation development and palatability testing, electronic tongue measurements were applied.
The electronic tongue measurement indicated taste-masking capabilities for three different formulations in the developmental phase. A glycerol-based formulation was further tested and compared to the reference formulation prepared out of crushed and suspended tablets. The mean difference (95% CI) in VAS scores between both formulations, as indicated by the children (n = 20), was 2.4 (-8.5, 13) mm, in favour of the new paediatric valaciclovir formulation. The mean (95% CI) difference in VAS scores indicated by the parents (n = 20) was -0.9 (-12, 9.8) mm.
The palatability of the new paediatric valaciclovir formulation was considered non-inferior to the reference formulation prepared out of crushed tablets. We were able to optimize the study design and number of children to be included in the palatability testing by using electronic tongue measurements.
评估伐昔洛韦新儿科制剂在儿童及其父母中的适口性:研究新儿科制剂(试验制剂)与参比制剂相比的非劣效性。
在一项随机、两阶段、多中心、交叉研究中进行体内适口性测试。儿童及其父母使用100毫米视觉模拟量表(VAS)对新儿科伐昔洛韦制剂和参比制剂的喜好程度进行评分。为支持制剂开发和适口性测试,应用了电子舌测量。
电子舌测量表明处于研发阶段的三种不同制剂具有掩味能力。对一种基于甘油的制剂进行了进一步测试,并与由碾碎和混悬片剂制备的参比制剂进行比较。儿童(n = 20)给出的两种制剂VAS评分的平均差值(95%CI)为2.4(-8.5,13)毫米,新儿科伐昔洛韦制剂更受青睐。父母(n = 20)给出的VAS评分平均(95%CI)差值为-0.9(-12,9.8)毫米。
新儿科伐昔洛韦制剂的适口性被认为不劣于由碾碎片剂制备的参比制剂。通过使用电子舌测量,我们能够优化研究设计和适口性测试中纳入的儿童数量。